- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05638581
Traumareanimatie met lage titer groep O volbloed of producten (TROOP)
The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.
The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.
The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- University of Alabama at Birmingham, UAB Hospital
-
-
California
-
Los Angeles, California, Verenigde Staten, 90033
- Los Angeles County + University of Southern California (LAC + USC) Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70112
- University Medical Center New Orleans LCMC Health
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- University of Maryland Medical Center
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45267
- University of Cincinnati Medical Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Sciences University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Penn Presbyterian Medical Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas Health Science Center Houston
-
San Antonio, Texas, Verenigde Staten, 78229
- University of Texas Health San Antonio and University Health System
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- Harborview Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Froedtert Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)
-
Patient taken to trauma center directly from scene
-
Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting
-
Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol
-
Traumatic injury with at least one of the following:
- Confirmed or suspected acute major bleeding
- Assessment of Blood Consumption (ABC) Score ≥2
Exclusion Criteria:
- Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
- Patients transferred from another hospital
- Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
- Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
- Moribund patients expected to die within 1 hour
- Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
- Patients with known "do not resuscitate" orders prior to randomization
- Patients who refuse the administration of blood products
- Individuals with a research "opt out" bracelet.
- Greater than 20% total body surface area (TBSA) burns
- Suspected inhalation injury victims
- Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: LTOWB
Participants randomized to receive (Low Titer O Whole Blood [LTOWB]) |
Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously. |
|
Actieve vergelijker: Components
Participants randomized to receive the component blood products. |
Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
6-hour Mortality
Tijdsspanne: First 6 hours after randomization
|
Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant) |
First 6 hours after randomization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
24-hour Mortality
Tijdsspanne: First 24 hours after randomization
|
Participant vital status at 24-hours following randomization |
First 24 hours after randomization
|
|
Hospital/30-day Mortality
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Incidence of Pre-specified Complications
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Adjudicated Primary Cause of Death
Tijdsspanne: 30-days post randomization
|
Primary cause of death as reviewed and determined by the study investigators (consensus) |
30-days post randomization
|
|
Length of Stay (Hospital and Intensive Care Unit)
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Number of hours hospitalized (includes both hospital and intensive care unit time) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Hospital-, Ventilator- and Intensive Care Unit-free days
Tijdsspanne: 30-days post randomization
|
Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit. |
30-days post randomization
|
|
Incidence of major surgical procedures
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The proportion of participants undergoing major surgical procedures. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Time to hemostasis in those undergoing procedures with a hemostatic component
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Tijdsspanne: First 24 hours after randomization
|
The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.) |
First 24 hours after randomization
|
|
Discharge destination
Tijdsspanne: At hospital discharge or 30-days post randomization (whichever the earlier)
|
Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc. |
At hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Functional status
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Patient's quality of life
Tijdsspanne: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham
Publicaties en nuttige links
Algemene publicaties
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Jansen JO, Pedroza C, Novelo LL, Hao T, DeWildt GR, Coton CF, Mansoor K, Stephens SW, Marques MB, Stubbs JR, Richter JR, Wang HE, Holcomb JB, DeSantis SM. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial). Trials. 2025 Aug 2;26(1):266. doi: 10.1186/s13063-025-08971-y.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB-300010517
- 1UG3HL157401-01A1 (Subsidie/contract van de Amerikaanse NIH)
- 1U24HL157310-01A1 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .